VEGF-话题@MedSci

#VEGF#

104篇内容 | 1523人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1368538, encodeId=9e831368538b5, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=诺华的抗血管内皮生长因子（VEGF）单抗Beovu获欧盟批准，用于治疗年龄相关的湿性黄斑变性, objectType=article, longId=188479, objectId=2f351884e941, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f351884e941, replyNumber=0, likeNumber=43, createdTime=2020-02-22, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f351884e941, moduleTitle=诺华的抗血管内皮生长因子（VEGF）单抗Beovu获欧盟批准，用于治疗年龄相关的湿性黄斑变性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f351884e941)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368537, encodeId=3d57136853ef6, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=老年黄斑变性（AMD）的治疗新思路：Nomacopan抑制补体活化，降低VEGF水平, objectType=article, longId=186921, objectId=12411869213e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12411869213e, replyNumber=0, likeNumber=36, createdTime=2020-01-30, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12411869213e, moduleTitle=老年黄斑变性（AMD）的治疗新思路：Nomacopan抑制补体活化，降低VEGF水平, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=12411869213e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368536, encodeId=7a56136853619, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=罗氏PD-L1单抗Tecentriq联合VEGF单抗Avastin组合治疗肝癌的III期临床成功, objectType=article, longId=181787, objectId=0d52181e8763, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d52181e8763, replyNumber=0, likeNumber=20, createdTime=2019-10-24, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d52181e8763, moduleTitle=罗氏PD-L1单抗Tecentriq联合VEGF单抗Avastin组合治疗肝癌的III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d52181e8763)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368535, encodeId=5f99136853548, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=Blood：止血通过释放和激活VEGFC刺激淋巴管生成, objectType=article, longId=180493, objectId=e52e180493f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e52e180493f0, replyNumber=0, likeNumber=37, createdTime=2019-10-05, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e52e180493f0, moduleTitle=Blood：止血通过释放和激活VEGFC刺激淋巴管生成, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e52e180493f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368534, encodeId=a5db13685342c, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=2019 ESMO：罗氏的PD-L1单抗Tecentriq与VEGF单抗Avastin联合针对无法切除的肝细胞癌患者的Ib期研究中显示出令人鼓舞的结果, objectType=article, longId=180179, objectId=775a1801e9d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=775a1801e9d4, replyNumber=0, likeNumber=38, createdTime=2019-09-29, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=775a1801e9d4, moduleTitle=2019 ESMO：罗氏的PD-L1单抗Tecentriq与VEGF单抗Avastin联合针对无法切除的肝细胞癌患者的Ib期研究中显示出令人鼓舞的结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=775a1801e9d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368533, encodeId=4676136853385, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=Sci Rep：Myoferlin沉默能够抑制VEGFR2介导的转移透明细胞肾细胞癌增殖, objectType=article, longId=179593, objectId=e0931e95934d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0931e95934d, replyNumber=0, likeNumber=0, createdTime=2019-09-18, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0931e95934d, moduleTitle=Sci Rep：Myoferlin沉默能够抑制VEGFR2介导的转移透明细胞肾细胞癌增殖, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0931e95934d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368532, encodeId=a777136853207, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=汪朝阳教授专访｜抗VEGF或能替代传统疗法, objectType=article, longId=179199, objectId=85941e91999b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85941e91999b, replyNumber=0, likeNumber=29, createdTime=2019-09-11, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85941e91999b, moduleTitle=汪朝阳教授专访｜抗VEGF或能替代传统疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85941e91999b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368531, encodeId=289313685315f, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=赵明威教授丨抗VEGF时代糖尿病视网膜病变诊疗策略, objectType=article, longId=179028, objectId=7c9f1e902837, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c9f1e902837, replyNumber=0, likeNumber=34, createdTime=2019-09-08, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c9f1e902837, moduleTitle=赵明威教授丨抗VEGF时代糖尿病视网膜病变诊疗策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c9f1e902837)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368530, encodeId=e47513685305d, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=Biomater Sci：BMP2-/VEGF转染的脂肪干细胞同时增强成骨和血管生成, objectType=article, longId=178796, objectId=e9081e879685, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e9081e879685, replyNumber=0, likeNumber=38, createdTime=2019-09-05, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e9081e879685, moduleTitle=Biomater Sci：BMP2-/VEGF转染的脂肪干细胞同时增强成骨和血管生成, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e9081e879685)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368529, encodeId=8e9213685291a, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=新型抗VEGF抗体聚合物KSI-301治疗湿性AMD、DME、RVO取得阶段成果, objectType=article, longId=176439, objectId=b2ea1e643956, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2ea1e643956, replyNumber=0, likeNumber=38, createdTime=2019-07-31, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2ea1e643956, moduleTitle=新型抗VEGF抗体聚合物KSI-301治疗湿性AMD、DME、RVO取得阶段成果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2ea1e643956)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368528, encodeId=d7c91368528db, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=FASEB J：BIG1和BIG2参与调节VEGF表达和血管生成, objectType=article, longId=173298, objectId=0a481e3298b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a481e3298b8, replyNumber=0, likeNumber=28, createdTime=2019-06-28, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a481e3298b8, moduleTitle=FASEB J：BIG1和BIG2参与调节VEGF表达和血管生成, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a481e3298b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368527, encodeId=299c136852ef2, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=Circulation：内皮细胞通过VEGFR2介导的旁分泌信号调节心肌生理性肥大, objectType=article, longId=167761, objectId=28c616e761c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28c616e761c2, replyNumber=0, likeNumber=36, createdTime=2019-06-07, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28c616e761c2, moduleTitle=Circulation：内皮细胞通过VEGFR2介导的旁分泌信号调节心肌生理性肥大, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28c616e761c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368526, encodeId=0304136852607, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=Iran Biomed J：新型聚腺苷二磷酸核糖聚合酶（RARP）抑制剂AZD2461能够下调VEGF表达和诱导前列腺癌细胞凋亡, objectType=article, longId=167119, objectId=81e116e11982, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=81e116e11982, replyNumber=0, likeNumber=0, createdTime=2019-05-31, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=81e116e11982, moduleTitle=Iran Biomed J：新型聚腺苷二磷酸核糖聚合酶（RARP）抑制剂AZD2461能够下调VEGF表达和诱导前列腺癌细胞凋亡, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=81e116e11982)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368525, encodeId=ed321368525c5, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=Front Physiol：人牙周 - 韧带干细胞的工程细胞外囊泡在骨再生期间增加VEGF / VEGFR2表达, objectType=article, longId=166771, objectId=4a7e166e7116, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a7e166e7116, replyNumber=0, likeNumber=25, createdTime=2019-05-26, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a7e166e7116, moduleTitle=Front Physiol：人牙周 - 韧带干细胞的工程细胞外囊泡在骨再生期间增加VEGF / VEGFR2表达, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a7e166e7116)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368524, encodeId=1de5136852427, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=FDA扩大了礼来的抗VEGFR2单抗Cyramza的适应症，用作肝癌患者的二线治疗, objectType=article, longId=165891, objectId=11a416589183, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11a416589183, replyNumber=0, likeNumber=36, createdTime=2019-05-13, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11a416589183, moduleTitle=FDA扩大了礼来的抗VEGFR2单抗Cyramza的适应症，用作肝癌患者的二线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11a416589183)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368523, encodeId=b78c13685238c, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=Stem Cells Dev：缺氧诱导因子1-α-AA修饰的骨髓干细胞部分通过VEGF/PI3K/Akt/FoxO1途径保护PC12细胞免受缺氧诱导, objectType=article, longId=165100, objectId=e628165100d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e628165100d0, replyNumber=0, likeNumber=30, createdTime=2019-04-29, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e628165100d0, moduleTitle=Stem Cells Dev：缺氧诱导因子1-α-AA修饰的骨髓干细胞部分通过VEGF/PI3K/Akt/FoxO1途径保护PC12细胞免受缺氧诱导, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e628165100d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368522, encodeId=53541368522e7, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=EASL：VEGFR2单抗Ramucirumab对晚期肝细胞癌的治疗有临床益处, objectType=article, longId=164528, objectId=3745164528c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3745164528c3, replyNumber=0, likeNumber=27, createdTime=2019-04-20, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3745164528c3, moduleTitle=EASL：VEGFR2单抗Ramucirumab对晚期肝细胞癌的治疗有临床益处, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3745164528c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368521, encodeId=a2841368521e0, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=Cancer Biomark：Circ0001429通过结合miR-205-5p和促进VEGFA表达来调节膀胱癌的进展, objectType=article, longId=163075, objectId=08cd1630e5c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08cd1630e5c1, replyNumber=0, likeNumber=18, createdTime=2019-03-29, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08cd1630e5c1, moduleTitle=Cancer Biomark：Circ0001429通过结合miR-205-5p和促进VEGFA表达来调节膀胱癌的进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08cd1630e5c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368520, encodeId=6b831368520b3, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=Macromol Biosci：VEGF-过表达人脂肪干细胞与WH增强冷冻凝胶对骨再生的成骨作用, objectType=article, longId=161640, objectId=02d316164041, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02d316164041, replyNumber=0, likeNumber=38, createdTime=2019-03-06, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02d316164041, moduleTitle=Macromol Biosci：VEGF-过表达人脂肪干细胞与WH增强冷冻凝胶对骨再生的成骨作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02d316164041)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368519, encodeId=f336136851935, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=达伯舒®联合抗VEGF单抗用于一线HCC的研究完成首例患者给药, objectType=article, longId=161437, objectId=0fed16143ef7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0fed16143ef7, replyNumber=0, likeNumber=28, createdTime=2019-03-02, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0fed16143ef7, moduleTitle=达伯舒®联合抗VEGF单抗用于一线HCC的研究完成首例患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0fed16143ef7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

VEGF

2020-05-29

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

诺华的抗血管内皮生长因子（VEGF）单抗Beovu获欧盟批准，用于治疗年龄相关的湿性黄斑变性

2020-02-22

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

老年黄斑变性（AMD）的治疗新思路：Nomacopan抑制补体活化，降低VEGF水平

2020-01-30

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

罗氏PD-L1单抗Tecentriq联合VEGF单抗Avastin组合治疗肝癌的III期临床成功

2019-10-24

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

Blood：止血通过释放和激活VEGFC刺激淋巴管生成

2019-10-05

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

2019 ESMO：罗氏的PD-L1单抗Tecentriq与VEGF单抗Avastin联合针对无法切除的肝细胞癌患者的Ib期研究中显示出令人鼓舞的结果

2019-09-29

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

Sci Rep：Myoferlin沉默能够抑制VEGFR2介导的转移透明细胞肾细胞癌增殖

2019-09-18

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

汪朝阳教授专访｜抗VEGF或能替代传统疗法

2019-09-11

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

赵明威教授丨抗VEGF时代糖尿病视网膜病变诊疗策略

2019-09-08

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

Biomater Sci：BMP2-/VEGF转染的脂肪干细胞同时增强成骨和血管生成

2019-09-05

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

新型抗VEGF抗体聚合物KSI-301治疗湿性AMD、DME、RVO取得阶段成果

2019-07-31

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

FASEB J：BIG1和BIG2参与调节VEGF表达和血管生成

2019-06-28

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

Circulation：内皮细胞通过VEGFR2介导的旁分泌信号调节心肌生理性肥大

2019-06-07

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

Iran Biomed J：新型聚腺苷二磷酸核糖聚合酶（RARP）抑制剂AZD2461能够下调VEGF表达和诱导前列腺癌细胞凋亡

2019-05-31

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

Front Physiol：人牙周 - 韧带干细胞的工程细胞外囊泡在骨再生期间增加VEGF / VEGFR2表达

2019-05-26

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

FDA扩大了礼来的抗VEGFR2单抗Cyramza的适应症，用作肝癌患者的二线治疗

2019-05-13

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

Stem Cells Dev：缺氧诱导因子1-α-AA修饰的骨髓干细胞部分通过VEGF/PI3K/Akt/FoxO1途径保护PC12细胞免受缺氧诱导

2019-04-29

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

EASL：VEGFR2单抗Ramucirumab对晚期肝细胞癌的治疗有临床益处

2019-04-20

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

Cancer Biomark：Circ0001429通过结合miR-205-5p和促进VEGFA表达来调节膀胱癌的进展

2019-03-29

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

Macromol Biosci：VEGF-过表达人脂肪干细胞与WH增强冷冻凝胶对骨再生的成骨作用

2019-03-06

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

达伯舒®联合抗VEGF单抗用于一线HCC的研究完成首例患者给药

2019-03-02

科室
- - 订阅+
  - 更多科室
工具
服务